Read by QxMD icon Read


Jakob R Passweg, Helen Baldomero, Peter Bader, Grzegorz W Basak, Chiara Bonini, Rafael Duarte, Carlo Dufour, Nicolaus Kröger, Jürgen Kuball, Arjan Lankester, Silvia Montoto, Arnon Nagler, John A Snowden, Jan Styczynski, Mohamad Mohty
Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic)...
March 14, 2018: Bone Marrow Transplantation
Zhuoyan Li, Myriam Labopin, Fabio Ciceri, Didier Blaise, Johanna Tischer, Gerhard Ehninger, M T Van Lint, Yener Koc, Stella Santarone, Edouard Forcade, Luca Castagna, Emmanuelle Polge, Audrey Mailhol, Annalisa Ruggeri, Mohamad Mohty, Bipin N Savani, Arnon Nagler
Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the EBMT aute leukemia working group (ALWP) registry. We identified 154 patients with sAML who underwent haploHCT from 2006-2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease...
March 14, 2018: American Journal of Hematology
Jan Styczynski, Gloria Tridello, J Peter Donnelly, Simona Iacobelli, Jennifer Hoek, Malgorzata Mikulska, Mahmoud Aljurf, Lidia Gil, Simone Cesaro
International guidelines on protective environment for HSCT recipients proposed a set of 10 global recommendations in 2009 on protective environment (GRPE) concerning hospital room design and ventilation. The EBMT Infectious Diseases Working Party undertook a survey on the status on protective environment for HSCT recipients with the aim of surveying current practices and their agreement with GRPE recommendations. The questionnaire consisted of 37 questions divided into 5 sections about filtration, air changes, maintenance, and the protective environment in rooms and the surrounding unit...
March 13, 2018: Bone Marrow Transplantation
Zinaida Peric, Stefano Botti, Jacqui Stringer, Joanna Krawczyk, Steffie van der Werf, Anja van Biezen, Mahmoud Aljurf, John Murray, Sarah Liptrott, Diana M Greenfield, Rafael F Duarte, Tapani Ruutu, Grzegorz W Basak
Recommendations on screening and nutritional support for patients undergoing hematopoietic stem cell transplantation (HSCT) have been presented by international nutritional societies, but nutritional practices remain poorly standardized. Following the general policy of the European Society for Blood and Marrow Transplantation (EBMT) to standardize transplantation procedures, the Complications and Quality of Life Working Party and Nursing Research Group carried out a survey among all EBMT centers about their current nutritional practices...
March 7, 2018: Bone Marrow Transplantation
Jonathan Canaani, Myriam Labopin, Xiao-Jun Huang, William Arcese, Fabio Ciceri, Didier Blaise, Giuseppe Irrera, Lucia Lopez Corral, Benedetto Bruno, Stella Santarone, Maria Teresa Van Lint, Antonin Vitek, Jordi Esteve, Mohamad Mohty, Arnon Nagler
Acute myeloid leukemia (AML) patients harboring the FLT3-ITD mutation are considered a high risk patient subset preferentially allocated for allogeneic stem cell transplantation in first remission. Whether FLT3-ITD retains a prognostic role in haploidentical stem cell transplantation (haplo-SCT) is unknown. To analyze the prognostic impact of FLT3-ITD in haplo-SCT, we performed a retrospective analysis of the multicenter registry of the acute leukemia working party of the European Society for Blood and Marrow Transplantation...
March 2, 2018: American Journal of Hematology
Simone Cesaro, Gloria Tridello, Nicole Blijlevens, Per Ljungman, Charles Craddock, Mauricette Michallet, Alexander Martin, John A Snowden, Mohamad Mohty, Johan Maertens, Jacob Passweg, Eefke Petersen, Anne Nihtinen, Cecilia Isaksson, Noel Milpied, Pierre-Simon Rohlich, Eric Deconinck, Charles Crawley, Marie-Pierre Ledoux, Jennifer Hoek, Arnon Nagler, Jan Styczynski
Objectives: To assess the incidence of, and risk factors for, Candida infection in the first 100 days after allogeneic hematopoietic stem cell transplantation (HSCT) and the impact on long-term survival. Methods: outcome analysis of 28,542 acute leukemia patients who underwent HSCT from 2000 to 2012: 347 with candidemia by day +100, and 28,195 without candidemia or any other type of Candida infection. Results: The incidence of candidemia by day +100 was 1...
February 22, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Adrien Picod, Agnès Bonnin, Giorgia Battipaglia, Federica Giannotti, Annalisa Ruggeri, Eolia Brissot, Florent Malard, Clémence Médiavilla, Ramdane Belhocine, Anne Vekhoff, Mor Sény Gueye, Simona Lapusan, Rosa Adaeva, Françoise Isnard, Ollivier Legrand, Minh-Tam Baylatry, Anne-Christine Joly, Myriam Labopin, Rémy Duléry, Mohamad Mohty
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD) is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT but the 2016 EBMT diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting but its value remains uncertain in the adult population. We report here a single center series of 63 adult patients considered at high risk of SOS/VOD, receiving defibrotide prophylaxis in combination with ursodeoxycholic acid between May 2012 and August 2016...
February 22, 2018: Biology of Blood and Marrow Transplantation
Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, Annalisa Ruggeri, Fernanda Volt, Annalisa Paviglianiti, Chantal Kenzey, Hiromi Hayashi, Jan Cornelissen, Mauricette Michallet, Dimitrios Karakasis, Eric Deconinck, Pierre-Simon Rohrlich, Regis Peffault de la Tour, Didier Blaise, Eefke Petersen, Maud D'Aveni, Henrik Sengeloev, Thierry Lamy, Nigel H Russell, Edouard Forcade, Charles F Craddock, Arnon Nagler, Eliane Gluckman, Vanderson Rocha
Usually, after double umbilical cord blood transplant (DUCBT) only one of the transplanted units persists long term. The characteristics of the winning cord blood unit (W-CBU) that determine unit dominance and how they influence the outcomes of DUCBT remain unclear. We retrospectively analysed 347 patients with acute leukaemia transplanted with a DUCBT (694 CBU) from 2005 to 2013 who had documented neutrophil engraftment and a W-CBU identified by chimerism analysis, in order to identify unit characteristics impacting on dominance...
February 22, 2018: Biology of Blood and Marrow Transplantation
Simona Sestili, Myriam Labopin, Annalisa Ruggeri, Andrea Velardi, Fabio Ciceri, Johan Maertens, Lothar Kanz, Franco Aversa, Philippe Lewalle, Donald Bunjes, Mohamad Mohty, Arnon Nagler
BACKGROUND: T-cell-depleted, haploidentical transplantations (haplos) are commonly offered to patients who have high-risk, acute leukemia in the absence of a human leukocyte antigen (HLA) full-matched donor. METHODS: To determine the effect of transplantation period, the authors divided 308 adults with de novo, acute leukemia who underwent T-cell-depleted haplo from 2005 to 2015 into 2 groups, according the year in which they underwent transplantation (2005-2011 [n = 191] and 2012-2015 [n = 117])...
February 22, 2018: Cancer
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Karl S Peggs, Didier Blaise, Boris Afanasyev, José L Diez-Martin, Jorge Sierra, Adrian Bloor, Carmen Martinez, Stephen Robinson, Ram Malladi, Jean El-Cheikh, Paolo Corradini, Silvia Montoto, Peter Dreger, Anna Sureda
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre-transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV...
February 22, 2018: British Journal of Haematology
Irit Avivi, Ariane Boumendil, Hervé Finel, Arnon Nagler, Aïda Botelho de Sousa, Josep Maria Ribera Santasusana, Elizabeth Vandenberghe, Boris Afanasyev, Dominique Bordessoule, José Maria Moraleda, Eulogio Conde Garcia, David Pohlreich, Gonzalo Gutiérrez Garcia, Kirsty Thomson, Reuven Or, Dietrich Beelen, Eliana Zuffa, Sebastian Giebel, Christian Berthou, Gilles Salles, Angela Melpignano, Silvia Montoto, Peter Dreger
The purpose of this retrospective registry study was to investigate the outcome of autoSCT for primary mediastinal B-cell lymphoma (PMBCL) in the rituximab era, including the effects of eventual post-transplant radiotherapy (RT) consolidation. Patients with PMBCL aged between 18 and 70 years who were treated with a first autoSCT between 2000 and 2012 and registered with the EBMT were eligible. Eighty-six patients with confirmed PMBCL and the full data set required for this analysis were evaluable. Sixteen patients underwent autoSCT in remission after first-line therapy (CR/PR1), 44 patients were transplanted with chemosensitive relapsed or primary refractory disease (CR/PR >1), and 24 patients were chemorefractory at the time of autoSCT...
February 20, 2018: Bone Marrow Transplantation
Anna Sureda, Mei-Jie Zhang, Peter Dreger, Jeanette Carreras, Timothy Fenske, Herve Finel, Harry Schouten, Silvia Montoto, Stephen Robinson, Sonali M Smith, Ariane Boumedil, Mehdi Hamadani, Marcelo C Pasquini
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long-term outcomes and associated factors among recipients of allo-HCT with FL. METHODS: Patients with relapsed FL who underwent allo-HCT from 2001 to 2011 with a human leukocyte antigen (HLA)-matched donor were included. Outcome analyses for overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and disease relapse/progression were calculated...
February 9, 2018: Cancer
Francesco Saraceni, Myriam Labopin, Rose-Marie Hamladji, Ghulam Mufti, Gerard Socié, Avichai Shimoni, Jeremy Delage, Eric Deconinck, Patrice Chevallier, Didier Blaise, Jaime Sanz, Anne Huynh, Edouard Forcade, Bipin N Savani, Mohamad Mohty, Arnon Nagler
Background: A preparatory regimen consisting of thiotepa-busulfan-fludarabine (TBF) has been associated with reduced relapse in patients with haematological malignancies after haploidentical and cord blood transplants; however, few data exist regarding TBF conditioning in sibling (MSD) and unrelated donor (URD) transplants for AML. Results: Among patients receiving a myeloablative (MAC) regimen, TBF-MAC was associated with significantly lower relapse (HR 0.47, p = 0...
January 9, 2018: Oncotarget
Nico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, Linda Koster, Hareth Nahi, Anne-Marie Stoppa, Tamás Masszi, Denis Caillot, Stig Lenhoff, Miklos Udvardy, Charles Crawley, William Arcese, Clara Mariette, Ann Hunter, Xavier Leleu, Martin Schipperus, Michel Delforge, Pietro Pioltelli, John A Snowden, Maija Itälä-Remes, Maurizio Musso, Anja van Biezen, Laurent Garderet, Nicolaus Kröger
We investigated extramedullary disease in newly diagnosed multiple myeloma patients and its impact on outcome following first line autologous stem cell transplantation. We identified 3744 adult myeloma patients who received upfront single (n = 3391) or tandem transplantation (n = 353) between 2005 and 2014 with available data on extramedullary in-volvement at diagnosis. The overall incidence of extramedullary disease was 18.2% (n = 682) and increased per year from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found in 543 (14...
February 1, 2018: Haematologica
Laurent Garderet, Simona Iacobelli, Linda Koster, Hartmut Goldschmidt, Jan-Erik Johansson, Jean Henri Bourhis, Marta Krejci, Xavier Leleu, Michael Potter, Didier Blaise, Christian Koenecke, Christian Peschel, Jakub Radocha, Bernd Metzner, Pascal Lenain, Kerstin Schäfer-Eckart, David Pohlreich, Mariella Grasso, Denis Caillot, Herman Einsele, Marco Ladetto, Stefan Schönland, Nicolaus Kröger
OBJECTIVES: To evaluate the outcome of a salvage third autologous stem cell transplantation (ASCT) in relapsed multiple myeloma. PATIENTS AND METHODS: We analyzed 570 patients who had received a third ASCT between 1997 and 2010 (EBMT data), of whom 482 patients had received tandem ASCT and a third ASCT at first relapse (AARA group) and 88 patients had an upfront ASCT with second and third transplants after subsequent relapses (ARARA group). RESULTS: With a median follow-up of 61 and 48 months after salvage third ASCT, the day 100 non-relapse mortality was 4% and 7%, the incidence of second primary malignancy was 6% and 7%, the median progression free survival was 13 and 8 months and median overall survival (OS) was 33 and 15 months (AARA and ARARA groups, respectively)...
February 2, 2018: Biology of Blood and Marrow Transplantation
Roni Bitterman, Noa Eliakim-Raz, Inbal Vinograd, Anca Zalmanovici Trestioreanu, Leonard Leibovici, Mical Paul
BACKGROUND: This is an update of the Cochrane review published in 2013, Issue 10.Immunosuppressed cancer patients are at increased risk of serious influenza-related complications. Guidelines, therefore, recommend influenza vaccination for these patients. However, data on vaccine effectiveness in this population are lacking, and the value of vaccination in this population remains unclear. OBJECTIVES: To assess the effectiveness of influenza vaccine in immunosuppressed adults with malignancies...
February 1, 2018: Cochrane Database of Systematic Reviews
Andrea Necchi, Salvatore Lo Vullo, Simona Secondino, Giovanni Rosti, Manuela Badoglio, Patrizia Giannatempo, Daniele Raggi, Francesco Lanza, Christian Chabannon, Chiara Bonini, Luigi Mariani, Paolo Pedrazzoli
We aimed to assess the incidence and risk factors of secondary malignancy (SM) in the young adult patients who received high-dose chemotherapy (HDCT) for germ cell tumors (GCT). The EBMT database was interrogated. Criteria for patient selection included adult male GCT and HDCT administered in any line of therapy. Cumulative incidence methods were used to estimate the time-to-SM diagnosis. Univariable Fine and Gray proportional hazard regression evaluated risk factors of SM occurrence. From 1981 to 2015, 9153 autografts were identified...
January 24, 2018: Bone Marrow Transplantation
Andreas Holbro, Helen Baldomero, Francesco Lanza, Christian Chabannon, John A Snowden, Andreas Buser, Laura Infanti, Nina Worel, Anna Sureda, Manuela Badoglio, Jakob Passweg, Chiara Bonini
BACKGROUND: There is considerable heterogeneity in processing of stem cells for hematopoietic stem cell transplantation across Europe. The Foundation for the Accreditation of Cellular Therapy (FACT)-Joint Accreditation Committee International Society for Cellular Therapy and European Society for Blood and Marrow Transplantation (EBMT) (JACIE) standards provide minimum guidelines that, however, leave room for significant variations in practices at the individual transplantation center (TC)...
January 15, 2018: Cytotherapy
Gabrielle Roth-Guepin, Jonathan Canaani, Annalisa Ruggeri, Myriam Labopin, Juergen Finke, Jan J Cornelissen, Jeremy Delage, Gernot Stuhler, Monserrat Rovira, Mike Potter, Michael Stadler, Hendrik Veelken, Jean Yves Cahn, Matthew Collin, Yves Beguin, Sebastian Giebel, Arnon Nagler, Mohamad Mohty
Hematopoietic stem cell transplantation (HSCT) is being increasingly explored as a treatment modality for older patients with acute lymphoblastic leukemia (ALL). Yet, concerns regarding the long term outcome of transplantation in older patients limit the wide spread applicability of this approach. In this analysis we set out to determine the outcome of ALL patients over the age of 60 who underwent reduced intensity HSCT. Herein, we present the experience of the acute leukemia working party (ALWP) of the EBMT in this age group...
December 22, 2017: Oncotarget
David Buchbinder, Debra Lynch Kelly, Rafael F Duarte, Jeffery J Auletta, Neel Bhatt, Michael Byrne, Zachariah DeFilipp, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne B Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary D E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and non-malignant diseases. Despite increasing survival rates, long-term morbidity following HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction following HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction following HCT...
January 17, 2018: Bone Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"